Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors

Biochemical and Biophysical Research Communications

Volumn 377, Issue 2, 2008, Pages 627-631

  Chau, My N ^a   Banerjee, Partha P ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

High throughput screening; Prostate cancer; STAT3 activators; STAT3 inhibitors; STAT3 reporter cell line

Indexed keywords

ANTINEOPLASTIC AGENT; CUCURBITACIN GLYCOSIDE; CUCURBITACIN I; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 6; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PUROMYCIN; STAT3 PROTEIN; STAT3 PROTEIN ACTIVATOR; STAT3 PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL NUCLEUS; CONTROLLED STUDY; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MALE; NUCLEAR LOCALIZATION SIGNAL; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL NUCLEUS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; STAT3 TRANSCRIPTION FACTOR; TRITERPENES; TYRPHOSTINS;

EID: 55549141133     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.10.025     Document Type: Article

References (30)

1. Horvath C.M., Wen Z., and Darnell Jr. J.E. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9 (1995) 984-994
2. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
3. Sun J., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., and Sebti S.M. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24 (2005) 3236-3245
4. Ni Z., Lou W., Leman E.S., and Gao A.C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 60 (2000) 1225-1228
5. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8 (2002) 945-954
6. Fernandes A., Hamburger A.W., and Gerwin B.I. ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int. J. Cancer 83 (1999) 564-570
7. Berclaz G., Altermatt H.J., Rohrbach V., Siragusa A., Dreher E., and Smith P.D. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. 19 (2001) 1155-1160
8. Calo V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., and Russo A. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197 (2003) 157-168
9. Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., Lisanti M.P., Zellweger T., Alanen K., Mirtti T., Visakorpi T., Bubendorf L., and Nevalainen M.T. Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172 (2008) 1717-1728
10. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
11. Chiu J.J., Sgagias M.K., and Cowan K.H. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. 2 (1996) 215-221
12. Turkson J., Bowman T., Garcia R., Caldenhoven E., De Groot R.P., and Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18 (1998) 2545-2552
13. Starr R., and Hilton D.J. Negative regulation of the JAK/STAT pathway. Bioessays 21 (1999) 47-52
14. Chung C.D., Liao J., Liu B., Rao X., Jay P., Berta P., and Shuai K. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278 (1997) 1803-1805
15. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzki A., Kraker A., and Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2001) 2499-2513
16. Barton B.E., Karras J.G., Murphy T.F., Barton A., and Huang H.F. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. 3 (2004) 11-20
17. Seidel H.M., Lamb P., and Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 19 (2000) 2645-2656
18. Huang C., Cao J., Huang K.J., Zhang F., Jiang T., Zhu L., and Qiu Z.J. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci. 97 (2006) 1417-1423
19. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63 (2003) 1270-1279
20. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
21. Lin T.S., Mahajan S., and Frank D.A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 19 (2000) 2496-2504
22. Lee S.O., Lou W., Qureshi K.M., Mehraein-Ghomi F., Trump D.L., and Gao A.C. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 60 (2004) 303-309
23. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., Irby R., Yeatman T., Courtneidge S.A., and Jove R. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98 (2001) 7319-7324
24. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., Jove R., and Yu H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59 (1999) 5059-5063
25. Tyagi A., Agarwal R., and Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 22 (2003) 1302-1316
26. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., Muro-Cacho C., Livingston S., Karras J., Pow-Sang J., and Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659-6666
27. Qureshi K., Lee S., Lou W., Trump D., and Gao A. Targeting stat3 signaling in human prostate cancer cells using tyrosine kinase inhibitors. J. Clin. Oncol., 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 (2004) 3138
28. Ueda T., Bruchovsky N., and Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277 (2002) 7076-7085
29. Schust J., Sperl B., Hollis A., Mayer T.U., and Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13 (2006) 1235-1242
30. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., Laudano A., Sebti S., Hamilton A.D., and Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276 (2001) 45443-45455